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Abstract
Objective To evaluate the efﬁcacy and safety proﬁles of
patients with hepatitis B e antigen (HBeAg)-positive
chronic hepatitis B (CHB) treated with adefovir dipivoxil
(ADV) or ADV plus bicyclol, and to optimize the treatment
strategy for CHB patients.
Patients and methods A total of250 patientswith HBeAg-
positive CHB were randomized to ADV plus bicyclol com-
bination group and ADV monotherapy group. The patients in
the ADV plus bicyclol combination therapy group (n = 125)
received ADV 10 mg orally q.d. and bicyclol 25 mg orally
t.i.d.for 48 weeks,and those intheADV monotherapy group
(n = 125) were administered ADV 10 mg orally q.d. alone
for 48 weeks. The serum aminotransferases (ALT/AST),
HBVDNA,HBeAg/HBeAb,andliverbiopsywereconducted
before and after therapy.
Results The serum aminotransferase levels were
decreased signiﬁcantly in both groups. The serum amino-
transferase level in ADV plus bicyclol combination therapy
group decreased greater than that in ADV monotherapy
group (P\0.01). The virological response rate in ADV
plus bicyclol combination therapy group was not signiﬁ-
cantly different from that in ADV monotherapy group
(P[0.05). After treatment for 48 weeks, the Knodell
necroinﬂammatory score of the two groups were all alle-
viated signiﬁcantly, and the Knodell score in the combi-
nation group was signiﬁcantly lower than that in the ADV
monotherapy group (P\0.05). There were no remarkable
adverse events probably related to the drug in this study.
Conclusion Adefovir dipivoxil plus bicyclol combination
therapy is a safe and superior treatment regimen for
patients with HBeAg-positive CHB when compared with
ADV monotherapy.
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Introduction
Chronic hepatitis B virus (HBV) infection is a major health
problem worldwide [1]. Carriers of HBV have increased
risk of developing cirrhosis, liver decompensation, and
hepatocellular carcinoma (HCC) [2]. About 15–40% of the
HBV carriers will develop serious liver diseases during
their lifetime [3]. The chronic hepatitis B (CHB) is
becoming a worldwide burden because the pathologic
mechanism is complex and it is difﬁcult to eradicate the
HBV completely [4]. Effective treatments are required to
prevent progression of CHB to cirrhosis, HCC, and death
[5]. Monotherapy using interferon (IFN) or nucleos(t)ide
W. Xie   Z. Lang   H. Zhao   J. Yan   J. Cheng (&)
Liver Center, Beijing Ditan Hospital,
Capital Medical University, 100015 Beijing, China
e-mail: jun.cheng.ditanhospital@gmail.com
G. Shi
Department of Infectious Diseases, Huashan Hospital,
Fudan University, Shanghai, China
H. Zhang
Department of Pediatric Hepatology,
The 302 Hospital of PLA, Beijing, China
G. Zhao
Department of Hepatology,
Tianjin Municipal Hospital of Infectious Diseases,
Tianjin, China
Z. Yu
Department of Infectious Diseases,
First Hospital, Zhengzhou University, Zhengzhou, China
123
Hepatol Int (2012) 6:441–448
DOI 10.1007/s12072-011-9294-7(NUC) analogs has strong clinical evidence [6, 7]. But only
a small percentage of HBeAg-positive CHB patients
experienced HBeAg loss or seroconversion after 1 year
therapy with IFN/pegylated IFN. Short-term treatment of
CHB patients with NUC is insufﬁcient and prolonged
therapy may result in high cost and drug resistance [8, 9].
The notion of combination therapy for CHB treatment has
been previously examined, yielding inconclusive results
[10]. It is an urgent task to have better strategies for the
future treatment of patients with CHB.
The ﬁnal goal of antiviral therapy for patients with CHB
is to reduce the incidence of end-stage liver diseases, and
increase the chance of living a longer, better life [11]. For
this purpose, the recent goal was to improve the liver
histology with either IFN/PEG–IFN or NUC [12]. Antiviral
therapy with either IFN/PEG-IFN or NUC has shown only
a partial improvement in liver histology [13]. Adefovir
dipivoxil (ADV) is an oral prodrug of adefovir, an analog
of adenosine monophosphate, widely used in the clinical
treatment of CHB patients [14]. The active intracellular
metabolite, adefovir diphosphate, inhibits HBV DNA
polymerase at levels much lower than those needed to
inhibit the human DNA polymerases [15]. Studies in vivo
and in vitro showed that adefovir could signiﬁcantly inhibit
the replication of HBV DNA in both wild type and YMDD
mutant type [16].
For hepatologists, especially in East Asian countries,
liver protectant drug played an important role in the
treatment of CHB patients for a long time before antiviral
therapy was made available [17]. Accumulated clinical
evidence demonstrated signiﬁcant histological improve-
ment after the liver protectant drug therapy [18]. Bicyclol
is 4, 40-dimethoxy-5, 6, 50,6 0-dimethylene-dioxy-2, 20-
dicarboxylate biphenyl, a widely used liver protectant drug
in China and other countries [19]. Although the mechanism
of action of bicyclol is largely unknown, its anti-liver
injury, anti-liver inﬂammation, and anti-liver ﬁbrosis
effects have been well established in the recent years [20].
Both experimental and clinical studies have shown that
bicyclol can signiﬁcantly reduce the experimental liver
injury and liver ﬁbrosis, and has signiﬁcant antiinﬂamma-
tory activity [21]. The mechanism of action is closely
related to the elimination of free radicals, protection of
membrane and mitochondrial functions, suppression of
oxidative damage, induction of vivo antioxidants, and
inhibition of the serum TNFa, and inﬂammatory cytokines
that were induced by chronic carbon tetrachloride injury
[22]. Recent studies indicate that bicyclol not only pro-
motes Th1-type cytokine-mediated immune responses but
also downregulates Th2-type cytokine-mediated immune
responses [23]. Bicyclol can reduce liver inﬂammation and
protect liver from cell injury, decrease collagen synthesis
and secretion, and promote the degradation and absorption
of collagen. Therefore, it can inhibit the formation and
development of liver ﬁbrosis [24].
Pilot antiviral drug plus liver protectant drug have been
proved to be effective for the treatment of CHB, but there
is no well-designed clinical study conducted till now. To
establish strong evidence for the antiviral plus liver pro-
tectant drug for CHB patients, we evaluated the efﬁcacy
and safety proﬁles by combining ADV with liver protectant
drug (bicyclol) on HBeAg-positive CHB patients in China,
and the results, especially the improvement in histology,
are obviously promising.
Patients and methods
Patient population
Altogether 250, including 182 male and 68 female patients
with HBeAg-positive CHB were enrolled in this study.
Average age of all patients was 35.4 years (18–60 years),
who had been diagnosed with CHB for C6 months. All the
patients were IFN/PEG–IFN or NUC treatment naive. The
baseline serum alanine aminotransferase (ALT) level was
2–10 times of the upper limit of the normal (ULN) for all
the patients. Serum HBsAg and HBV DNA continued to be
positive for [6 months. All the patients were HBeAg-
positive and -negative, with a serum HBV DNA level of
C1.0 9 10
6 copies/mL, and none had concomitant other
categories hepatitis virus infection. A total bilirubin level
was B3.0 mg/dL (50 lmol/L) and relatively stable
recently. Simultaneously, drug-induced hepatitis, alcoholic
hepatitis, and autoimmune hepatitis were excluded. A total
of 250 patients were randomly assigned to ADV mono-
therapy and ADV plus bicyclol combination therapy
groups.
Therapeutic schedule
Patients in the monotherapy group were treated with 10 mg
of ADV (Tianjin Institute of Pharmaceutical Research
Pharmaceutical Company, Limited, Tianjin, China)
(n = 125), and patients in the combination therapy group
with 10 mg of ADV plus 75 mg (25 mg, t.i.d.) of bicyclol
(Beijing Union Pharmaceutical Factory, Beijing, China)
(n = 125) daily, both for 48 weeks.
Other antiviral drugs and liver protectant drugs were not
allowed during the therapy.
Liver biochemistry and serological markers of HBV
The serum biochemistry parameters, including ALT and
AST, were determined every 12 weeks. HBV serological
markers, including HBsAg, anti-HBs, HBeAg, and anti-
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123HBeAg, were determined by a microparticle enzyme
immunoassay. Reagents used in the determination of liver
biochemistry and HBV serology were purchased from
Abbott Laboratories (USA). Real-time PCR was performed
to quantitatively detect the serum HBV DNA using the PG
HBV FQ-PCR kit (Shenzhen PG Biotech). The lower limit
detection of this system was 1,000 copies/ml.
Liver pathological examination
Liver biopsy
Liver biopsy was performed using a16 G needle, requiring
hepatic tissue C1 cm, including four and more than four
portal areas. Processing of the tissue and preparation of
microscopic sections were performed conventionally.
Thickness of the ﬁlms was 4 lm, and they were stained by
hematoxylin–eosin, silver impregnation method, and
Masson trichrome.
Evaluation of liver histopathology
The pathological expert was blinded to all sections at
baseline and 48 weeks of treatment for evaluating liver
histology activity index (HAI), necroinﬂammation, and
ﬁbrosis scores according to the Knodell necroinﬂammatory
score system [25].
Statistical analysis
All analyses were performed using SPSS version 16.0
(SPSS Inc, USA). The demographics of patients and viro-
logical response were compared by the Student’s t test
for continuous data and Chi-square test for dichotomous
data. A value of P\0.05 was considered statistically
signiﬁcant.
Ethical issue
A consent form was signed by each patient before enroll-
ment to the study.
Results
Eight patients withdrew from the study during 48 weeks
of treatment. Of the remaining 242 patients, 122
patients received 10 mg of ADV plus 75 mg of bicyclol
daily (combination therapy group), and 122 patients
received 10 mg of ADV alone (monotherapy group).
There were no signiﬁcant differences in the demo-
graphic or HBV disease characteristics between the two
groups (Table 1).
Biochemical responses
Serum ALT levels of patients at 24 and 48 weeks of
treatment in both ADV plus bicyclol combination therapy
group (39.8 ± 25.6 vs. 153.4 ± 68.8; 30.3 ± 14.1 vs.
153.4 ± 68.8) and ADV monotherapy group (66.1 ± 42.7
vs. 146.5 ± 59.3; 46.4 ± 30.3 vs. 146.5 ± 59.3) were
signiﬁcantly decreased when compared with the baseline
levels, respectively (Table 2; Fig. 1)( P\0.01,\0.01).
Serum AST levels of patients at 24 and 48 weeks of
treatment in both ADV plus bicyclol combination therapy
group (46.6 ± 26.9 vs. 136.3 ± 50.7; 40.8 ± 20.2 vs.
136.3 ± 50.7) and ADV monotherapy group (67.9 ± 38.7
vs. 132.2 ± 50.7; 48.2 ± 27.5 vs. 132.2 ± 50.7) were
signiﬁcantly decreased compared with baseline levels,
respectively (Table 2; Fig. 2)( P\0.01). At the 24 and
48 weeks of therapy, both ALT and AST levels of patients
in combination group (39.8 ± 25.6 vs. 66.1 ± 42.7;
30.3 ± 14.1 vs. 46.4 ± 30.3) were signiﬁcantly lower than
that of patients in the monotherapy group (46.6 ± 26.9 vs.
67.9 ± 38.7; 40.8 ± 20.2 vs. 48.2 ± 27.5), respectively
(Table 2; Figs. 1, 2)( P\0.01, P\0.01).
ALT normalization rates of patients in combination
therapy group at 12, 24, 36, and 48 weeks(48.4, 64.8, 70.5,
and 78.7%) were signiﬁcantly higher than that of patients
in monotherapy group (25.8, 42.5, 50.8, and 60.0%),
respectively (Table 3; Fig. 3)( P\0.01). AST normaliza-
tion rates of patients in combination therapy group at 12,
24, 36, and 48 weeks (44.3, 59.0, 63.9, and 68.7%) were
signiﬁcantly higher than that of patients in the mono-
therapy group (25.0, 40.0, 46.7, and 54.2%), respectively
(for week 12, 24, and 36, P\0.01; for week 48, P\0.05)
(Table 3; Fig. 4).
Table 1 Comparison of baseline characteristics of patients in ADV
monotherapy and ADV plus bicyclol combination therapy groups
Combination
therapy
(n = 125)
Monotherapy
(n = 125)
Age 35.2 ± 10.2 35.7 ± 11.3
BMI (kg/m
2) 21.5 ± 2.8 20.8 ± 3.1
Gender: female (%) 33/125 (26.4) 35/125 (28.0)
Time since diagnosis C2 years (%) 61/125 (48.8) 59/125 (47.2)
HBV DNA, log10 copies/mL 7.0 ± 1.3 6.9 ± 1.0
ALT (U/L) 153.4 ± 68.8 146.5 ± 59.3
ALT range (%)
2t oB5 9 ULN 76/125 (60.8) 75/125 (57.6)
[5 9 ULN 49/125 (39.2) 53/125 (42.4)
No signiﬁcant differences were observed for age, BMI, gender, time
since diagnosis, HBV DNA viral load, ALT levels of patients in ADV
monotherapy compared with ADV plus bicyclol combination therapy
groups
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At the end of treatment, the HBV DNA levels were found
to be signiﬁcantly decreased from 6.9 ± 1.0 log10 copies/
mL at baseline to 3.1 ± 1.2 log10 copies/mL at week 48 for
patients in the monotherapy group (P\0.01), and from
7.0 ± 1.0 to 3.3 ± 1.2 log10 copies/mL for patients in the
combination therapy group (P\0.01). The HBV DNA lev-
els, however, had no signiﬁcant difference between the
monotherapy group (3.1 ± 1.2 log10 copies/mL) and the
combination therapy group (3.3 ± 1.2 log10 copies/mL) at
week 48 (Table 3)( P[0.05). At the end of treatment, per-
centages of patients with HBV DNA B1,000 log10 copies/
mL,HBeAgloss,andHBeAgseroconversioninmonotherapy
group (31.7, 25.8, and 18.3%, respectively) were not signiﬁ-
cantlydifferenttothatinthecombinationtherapygroup(34.4,
29.5, and 20.5%, respectively) (Table 3).
Histological improvements
Liver biopsy was performed twice in 87 patients, at base-
line and after treatment at week 48, with 45 patients in the
ADV plus bicyclol combination therapy group and 42
patients in the ADV monotherapy group. Average Knodell
necroinﬂammatory score was found to be signiﬁcantly
decreased from 7.0 ± 3.0 at baseline to 4.6 ± 2.8 at week
48 for patients in monotherapy group, and from 7.4 ± 2.9
at baseline to 3.5 ± 2.0 at week 48 for patients in combi-
nation therapy group (P\0.01). After 48 weeks of treat-
ment, Knodell necroinﬂammatory score reduction in
combination therapy group was signiﬁcantly greater than
that in monotherapy group (3.8 ± 2.9 vs. 2.4 ± 2.3,
respectively) (Table 4)( P\0.05).
Typical histology improvements were observed, for
example in two cases, No. 1 and No. 2. Necroinﬂammatory
degreesdecreasedsigniﬁcantlyattheendoftherapy(Figs. 5b,
6b) comparing with baseline (Figs. 5a, 6a), respectively.
Safety proﬁles
There were no serious adverse events during the course of
this study. In 125 treated patients, 15 had 12.0% adverse
events. In 125 patients from the ADV monotherapy group,
18 had 14.4% adverse events. The difference was not sta-
tistically signiﬁcant. All the adverse events were nonspe-
ciﬁc, including respiratory infections, lower limb pain,
bleeding gums, rashes, diarrhea, insomnia, etc (Table 5).
During therapy uncomfortable symptoms were almost
relieved after symptomatic treatment. There was no
Table 2 Dynamic changes of
ALT and AST levels during
treatment (x ± s, U/L)
a Compared to baseline level,
P\0.01
b Compared to ADV
monotherapy group, P\0.01
No. (n) Baseline 24 weeks 48 weeks
ALT
Monotherapy 120 146.5 ± 59.3 66.1 ± 42.7 46.4 ± 30.3
Combination 122 153.4 ± 68.8 39.8 ± 25.6
a 30.3 ± 14.1
a,b
AST
Monotherapy 120 133.2 ± 50.7 67.9 ± 38.7 48.2 ± 27.5
Combination 122 136.3 ± 50.7 46.6 ± 26.9
a 40.8 ± 20.2
a,b
153.4
39 9*#
30 3*#
146.5
66.1
46.4
0
5
10
15
20
25
Baseline 24 weeks 48 weeks
Combination
Monotherapy
Fig. 1 Baseline average ALT level for patients in ADV monotherapy
group is not signiﬁcantly different to that of ADV plus bicyclol
combination therapy group. At weeks 24 and 48 of treatment, ALT
levels were signiﬁcantly decreased for patients in both groups
compared with that of baseline levels (*P\0.01), ALT levels
decreased more signiﬁcantly in combination therapy group than that
in monotherapy group, respectively (
#P\0.01)
40.8*
46.6*
136.3
48.2
67.9
133.2
0.00
50.00
100.00
150.00
200.00
250.00
Baseline 24 weeks 48 weeks
Combination
Monotherapy
Fig. 2 Baseline average AST level for patients in ADV monotherapy
group is not signiﬁcantly different to that of ADV plus bicyclol
combination therapy group. At weeks 24 and 48 of treatment, AST
levels were signiﬁcantly decreased for patients in both groups
compared with that of baseline levels (*P\0.01), AST levels
decreased more signiﬁcantly in combination therapy group than that
in monotherapy group, respectively (
#P\0.01)
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123incidence of study drugs being discontinued because of
adverse events. No drug-related severe adverse events and
laboratory abnormalities were observed. Renal function
was checked during treatment, including serum creatinine
and blood urea nitrogen. No signiﬁcant differences were
observed for creatinine and blood urea nitrogen levels at
baseline and at 48 weeks therapy.
Discussion
Oral NUC is easily acceptable by the CHB patients for its
convenience and few side effects [26]. After a short period
of treatment, most of the patients were able to achieve
undetectable HBV DNA. Although HBV DNA response is
usually satisﬁed, histological improvement is quite limited
[27]. To optimize histological improvement and look for
long-term beneﬁts for patients with CHB, de novo com-
bination therapy is one of the options. ADV is widely used
in the clinical treatment of CHB patients. Domestic and
foreign clinical trials showed that it decreased the serum
HBV DNA and ALT levels, improved liver histology in
both HBeAg-positive and HBeAg-negative patients with
CHB, and resulted in HBeAg seroconversion in HBeAg-
positive patients. Treatment has been found to be safe and
well tolerated, with a low incidence of adverse events [28].
But ADV is usually used as monotherapy. Bicyclol is a
liver protectant drug for patients with various liver diseases
including viral hepatitis, drug-induced liver injuries, alco-
hol liver diseases, and autoimmune liver diseases in many
countries [29]. Clinical studies demonstrated that bicyclol
treatment for a year could achieve signiﬁcant improvement
in liver histology for various kinds of liver diseases [30].
For both ADV and bicyclol, monotherapy only could
achieve limited liver histological improvement. It is thus
reasonable to explore the combination therapy using ADV
plus bicyclol for the treatment of CHB patients.
Bicyclol is a widely used liver protectant drug in China
and other countries. Clinical trial was performed by double
blind, randomized, and positive control or placebo method
in multi-medical centers in China, using bicyclol 25 mg
thrice daily for 6 months demonstrating ALT AST nor-
malization in 50% of the patients with chronic viral
Table 3 Comparison of ALT, AST normalization rates in two groups during treatment and virological responses in two treatment groups at
48 weeks
Group ALT normalization rates AST normalization rates Serological markers of HBV at 48 week
12 week 24 week 48 week 12 week 24 week 48 week HBV DNA
B 1,000
copies/mL
HBeAg
loss
HBeAg
seroconversion
Monotherapy
%( n)
25.8
(31/120)
42.5
(51/120)
60.0
(72/120)
25.0
(30/120)
40.0
(48/120)
54.2
(65/120)
31.7
(38/120)
25.8
(31/120)
18.3
(22/120)
Combination
%( n)
48.4
(59/122)
a
64.8
(79/122)
a
78.7
(96/122)
a
44.3
(54/122)
a
59.0
(72/122)
a
68.7
(83/122)
b
34.4
(42/122)
29.5
(36/122)
20.5
(25/122)
a Compared to ADV monotherapy group, P\0.01
b P\0.05
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Fig. 3 Rates of ALT normalization at the weeks 12, 24, 36, and 48 of
the treatment in patients of ADV plus bicyclol combination therapy
group were signiﬁcantly higher than that in ADV monotherapy group,
respectively (*P\0.01)
Table 4 Comparison of Knodell necroinﬂammatory scores in two groups at 48 weeks of therapy
Group Necroinﬂammatory scores (x ± s) Fibrosis scores (x ± s)
Baseline At 48 weeks Reduction Baseline At 48 weeks Reduction
Monotherapy 7.0 ± 3.0 4.6 ± 2.8
a 2.4 ± 2.3 1.6 ± 0.91 1.0 ± 0.66 0.5 ± 0.2
Combination therapy 7.4 ± 2.9 3.5 ± 2.0
a 3.8 ± 2.9
b 2.0 ± 1.0 1.2 ± 0.8 0.7 ± 0.3
a Compared to the baseline scores, P\0.01
b Compared to ADV monotherapy group, P\0.05
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123hepatitis B and C. Eight articles reported the efﬁcacy of the
combination therapy of lamivudine plus bicyclol and
lamivudine or bicyclol used alone [31]. The results are
brieﬂy summarized as follows: total of more than 200 CHB
patients enrolled in the trials were previously treated with
lamivudine, some of them had already developed drug
resistance to lamivudine because of YMDD development.
The schedule of treatment was lamivudine 100 mg, q.d.
plus bicyclol 25 or 50 mg, t.i.d. p.o. for 24 or 48 weeks. In
general, at the end of combination therapy of lamivudine
plus bicyclol, the effectiveness of anti-HBV DNA and
negative of HBeAg were higher than lamivudine or bi-
cyclol used alone, particularly the YMDD mutant, and
relapse rate of virus markers was reduced. Two articles
reported the therapeutic effect of IFNa-2b alone and in
combination with bicyclol in CHB. In general, as compared
to INFa-2b treatment alone, the combination of bicyclol
with INFa-2b increased the improvement of the abnormal
liver function and HBV-DNA negative, and reduced
adverse reaction of INFa-2b.
To use ADV and bicyclol in combination therapy for
CHB patient, one concern might be the drug–drug inter-
action, and its effects on treatment and safety proﬁles.
From this trial, we did not observe more side effects in the
combination therapy group than in ADV monotherapy
group, indicating de novo combination therapy of these two
drugs is safe. Because of the complexity of bicyclol
function, the inﬂuence of the drug on ADV antiviral effect
is yet to be elucidated. From the percentages of patients
with HBV DNA B1,000 log10 copies/mL, HBeAg loss, and
HBeAg seroconversion at the end of therapy, there were no
0
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Fig. 4 Rates of AST normalization at weeks 12, 24, and 36 of the
treatment in patients of ADV plus bicyclol combination therapy group
were signiﬁcantly higher than that in ADV monotherapy group,
respectively (*P\0.01). Rate of AST normalization at week 48 of
the treatment in patients of ADV plus bicyclol combination therapy
group is signiﬁcantly higher than that in ADV monotherapy group
(
#P\0.05)
Fig. 5 Necroinﬂammation and
ﬁbrosis scores of patient No. 1
were signiﬁcantly improved
after 48 weeks therapy
(b) compared with baseline
(a) using ADV plus bicyclol
Table 5 Comparison of adverse events incidence of patients in ADV
monotherapy and ADV plus bicyclol combination therapy groups
Combination
(15/125)
Monotherapy
(18/125)
Respiratory infection 5 6
Lower limb pain 3 5
Bleeding gum 3 3
Rashes 2 2
Diarrhea 1 1
Insomnia 1 1
No signiﬁcant differences were observed in ADV monotherapy
comparing with ADV plus bicyclol combination therapy groups
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123signiﬁcant differences between monotherapy and combi-
nation therapy groups, demonstrating that the addition of
liver protectant drug bicyclol to ADV antiviral therapy did
not affect the ADV antiviral efﬁcacy. Nevertheless, a signif-
icant histological improvement has been conﬁrmed for both
monotherapy and combination therapy groups. At the same
time, this study clearly revealed that de novo combination of
ADV plus bicyclol could achieve even better histological
improvement for HBeAg-positive CHB patients.
The advantage of using de novo combination of ADV
and bicyclol could be seen as early as 12 weeks of therapy.
From week 12, the rates of ALT and AST normalization for
patients with combination therapy were signiﬁcantly
superior to that of patients on monotherapy. In combination
with the more signiﬁcant improvement in liver histology at
the end of therapy and the safety proﬁle of this de novo
combination therapy, the result of this study convinced us
for its value in exploring a better treatment regimen for
CHB patients.
To ﬁnally establish a new strategy for patients with
CHB, a prolonged treatment and long-term follow-up are
needed. The mechanism for potential drug interaction,
treatment efﬁcacy, and factors determining the efﬁcacy of
this combination therapy await further elucidation. Various
combinations with different NUC and liver protectant
drugs [32] are also the clinical interests in the future.
Because of the limited number of cases included in this
study, and comparatively short-term treatment, it is
required to expand the sample size and extend the treat-
ment duration to have ﬁrm conclusion. Optimized
treatment course and long-term follow-up after cessation of
the treatment are also important in future.
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